Global Glioma Therapeutics Market 2019-2023
About this market
Strategic alliances to drive growth in the market. Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma. Technavio’ s analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.
Market Overview
Expected approval of late-stage pipeline molecules
As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.
Availability of alternative therapies
Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients’ inclination toward the surgical and radiation treatment options.
For the detailed list of factors that will drive and challenge the growth of the glioma therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including NextSource Biotechnology and Novartis the competitive environment is quite intense. Factors such as the expected approval of late-stage pipeline molecules and the strategic alliances, will provide considerable growth opportunities to glioma therapeutics manufactures. F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis are some of the major companies covered in this report.
PRESS RELEASE
Technavio Announces the Publication of its Research Report – Global glioma therapeutics Market 2019-2023
Technavio recognizes the following companies as the key players in the global glioma therapeutics market: F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the strategic alliances.”
According to the report, one of the major drivers for this market is the expected approval of late-stage pipeline molecules.
Companies Mentioned
F. Hoffmann-La Roche
Merck Sharp & Dohme
Mylan
NextSource Biotechnology
Novartis
- Executive summary
- Scope of the report
- Preface
- Currency conversion rates for US$
- Market landscape
- Market ecosystem
- Table Global oncology therapeutics market
- Table Segments of global oncology therapeutics market
- Market characteristics
- Table Market characteristics
- Market segmentation analysis
- Table Market segments
- Market ecosystem
- Market sizing
- Market definition
- Table Market definition - Inclusions and exclusions checklist
- Market sizing 2018
- Table Market size 2018
- Market size and forecast 2018-2023
- Table Global market: Size and forecast 2018-2023 ($ millions)
- Table Global market: Year-over-year growth 2019-2023 (%)
- Market definition
- Five forces analysis
- Table Five forces analysis 2018
- Table Five forces analysis 2023
- Bargaining power of buyers
- Table Bargaining power of buyers
- Bargaining power of suppliers
- Table Bargaining power of suppliers
- Threat of new entrants
- Table Threat of new entrants
- Threat of substitutes
- Table Threat of substitutes
- Threat of rivalry
- Table Threat of rivalry
- Market condition
- Table Market condition - Five forces 2018
- Market segmentation by product
- Table Product - Market share 2018-2023 (%)
- Comparison by product
- Table Comparison by product
- Small molecules - Market size and forecast 2018-2023
- Table Small molecules - Market size and forecast 2018-2023 ($ millions)
- Table Small molecules - Year-over-year growth 2019-2023 (%)
- Biologics - Market size and forecast 2018-2023
- Table Biologics - Market size and forecast 2018-2023 ($ millions)
- Table Biologics - Year-over-year growth 2019-2023 (%)
- Market opportunity by product
- Table Market opportunity by product
- Customer landscape
- Table Customer landscape
- Geographic landscape
- Geographic segmentation
- Table Market share by geography 2018-2023 (%)
- Geographic comparison
- Table Geographic comparison
- Americas - Market size and forecast 2018-2023
- Table Americas - Market size and forecast 2018-2023 ($ millions)
- Table Americas - Year-over-year growth 2019-2023 (%)
- Table Top 3 countries in Americas
- EMEA - Market size and forecast 2018-2023
- Table EMEA - Market size and forecast 2018-2023 ($ millions)
- Table EMEA - Year-over-year growth 2019-2023 (%)
- Table Top 3 countries in EMEA
- APAC - Market size and forecast 2018-2023
- Table APAC - Market size and forecast 2018-2023 ($ millions)
- Table APAC - Year-over-year growth 2019-2023 (%)
- Table Top 3 countries in APAC
- Key leading countries
- Table Key leading countries
- Market opportunity
- Table Market opportunity
- Geographic segmentation
- Decision framework
- Drivers and challenges
- Market drivers
- Table Some of the therapeutics that received orphan drug designation from the US FDA are mentioned below
- Market challenges
- Table Impact of drivers and challenges
- Market drivers
- Market trends
- Vendor landscape
- Overview
- Table Vendor landscape
- Landscape disruption
- Table Landscape disruption
- Competitive scenario
- Overview
- Vendor analysis
- Vendors covered
- Table Vendors covered
- Vendor classification
- Table Vendor classification
- Market positioning of vendors
- Table Market positioning of vendors
- F. Hoffmann-La Roche
- Table F. Hoffmann-La Roche - Vendor overview
- Table F. Hoffmann-La Roche - Business segments
- Table F. Hoffmann-La Roche - Organizational developments
- Table F. Hoffmann-La Roche - Geographic focus
- Table F. Hoffmann-La Roche - Segment focus
- Table F. Hoffmann-La Roche - Key offerings
- Table F. Hoffmann-La Roche - Key customers
- Merck Sharp & Dohme
- Table Merck Sharp & Dohme - Vendor overview
- Table Merck Sharp & Dohme - Business segments
- Table Merck Sharp & Dohme - Organizational developments
- Table Merck Sharp & Dohme - Geographic focus
- Table Merck Sharp & Dohme - Segment focus
- Table Merck Sharp & Dohme - Key offerings
- Table Merck Sharp & Dohme - Key customers
- Mylan
- Table Mylan - Vendor overview
- Table Mylan - Business segments
- Table Mylan - Organizational developments
- Table Mylan - Geographic focus
- Table Mylan - Key offerings
- Table Mylan - Key customers
- NextSource Biotechnology
- Table NextSource Biotechnology - Vendor overview
- Table NextSource Biotechnology - Organizational developments
- Table NextSource Biotechnology - Key offerings
- Table NextSource Biotechnology - Key customers
- Novartis
- Table Novartis - Vendor overview
- Table Novartis - Business segments
- Table Novartis - Organizational developments
- Table Novartis - Geographic focus
- Table Novartis - Segment focus
- Table Novartis - Key offerings
- Table Novartis - Key customers
- Vendors covered
- Appendix
- Research methodology
- List of abbreviations
- Explore Technavio
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook